Screening and management of coccidioidomycosis in patients with inflammatory bowel disease on immunosuppressive therapies
- 13 October 2026
- journal article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Abstract
No abstract availableFunding Information
- Crohn’s and Colitis Foundation Career Development (#1282692)
This publication has 10 references indexed in Scilit:
- Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-AnalysisClinical Gastroenterology and Hepatology, 2022
- Coccidioidomycosis in patients with various inflammatory disorders treated with tumor necrosis factor α inhibitorsMedical Mycology, 2021
- Pulmonary CoccidioidomycosisSeminars in Respiratory and Critical Care Medicine, 2020
- Management of asymptomatic coccidioidomycosis in patients with rheumatic diseasesRheumatology International, 2019
- Approach to Management of Coccidioidomycosis in Patients Receiving Inhibitors of Tumor Necrosis Factor-αInfectious Diseases in Clinical Practice, 2017
- Risk Factors for Disseminated Coccidioidomycosis, United StatesEmerging Infectious Diseases, 2017
- Crohn’s Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With AdalimumabAmerican Journal of Gastroenterology, 2016
- 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of CoccidioidomycosisClinical Infectious Diseases, 2016
- Risk Factors for Targeted Fungal and Mycobacterial Infections in Patients Taking Tumor Necrosis Factor InhibitorsArthritis & Rheumatology, 2015
- Characteristics of Patients with Mild to Moderate Primary Pulmonary CoccidioidomycosisEmerging Infectious Diseases, 2014